KATIE GOOD: Open Payments
NPI 1093966178 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$431 in 14 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $115 · 2025 $431
Food & beverage: $262Education: $168
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $130 |
| Janssen Biotech, Inc. | 2 | $122 |
| Stemline Therapeutics Inc. | 2 | $40 |
| Daiichi Sankyo Inc. | 2 | $38 |
| Gilead Sciences, Inc. | 1 | $31 |
| Incyte Corporation | 1 | $26 |
| KYOWA KIRIN, INC. | 1 | $25 |
| Novartis Pharmaceuticals Corporation | 1 | $19 |
Products named: ERLEADA, IMFINZI, LYNPARZA, Orserdu, Enhertu, Trodelvy, MONJUVI, POTELIGEO.
Industry payments across TX — which companies pay providers there.
